170 related articles for article (PubMed ID: 37710391)
1. Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma.
Yesharim L; Teimourian S
Cancer Biol Ther; 2023 Dec; 24(1):2253586. PubMed ID: 37710391
[TBL] [Abstract][Full Text] [Related]
2. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
[TBL] [Abstract][Full Text] [Related]
3. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
4. Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
Dong S; Men W; Yang S; Xu S
Oncol Rep; 2020 May; 43(5):1437-1450. PubMed ID: 32323809
[TBL] [Abstract][Full Text] [Related]
5. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics study on genes related to a high-risk postoperative recurrence of lung adenocarcinoma.
Lin X; Zhou M; Xu Z; Chen Y; Lin F
Sci Prog; 2021; 104(3):368504211018053. PubMed ID: 34304612
[TBL] [Abstract][Full Text] [Related]
7. Identification of hub driving genes and regulators of lung adenocarcinoma based on the gene Co-expression network.
Xu Z; Wu Z; Xu J; Zhang J; Yu B
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32196072
[TBL] [Abstract][Full Text] [Related]
8. Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.
Wang Z; Li X; Chen H; Han L; Ji X; Wang Q; Wei L; Miao Y; Wang J; Mao J; Zhang Z
Med Sci Monit; 2021 May; 27():e929333. PubMed ID: 33979320
[TBL] [Abstract][Full Text] [Related]
9. High Expression of
Deng H; Huang Y; Wang L; Chen M
Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
[TBL] [Abstract][Full Text] [Related]
10. Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Hua P; Zhang Y; Jin C; Zhang G; Wang B
Medicine (Baltimore); 2020 Oct; 99(43):e22727. PubMed ID: 33120770
[TBL] [Abstract][Full Text] [Related]
11. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Hub Genes and Infiltrating Immune Cells in Non-Smoking Females with Lung Adenocarcinoma by Integrated Bioinformatic Analysis.
Li J; Wang B; Li X; Zhu Y
Med Sci Monit; 2020 Jul; 26():e922680. PubMed ID: 32669531
[TBL] [Abstract][Full Text] [Related]
13. Identification of differentially expressed genes associated with lung adenocarcinoma via bioinformatics analysis.
Yang X; Feng Q; Jing J; Yan J; Zeng Z; Zheng H; Cheng X
Gen Physiol Biophys; 2021 Jan; 40(1):31-48. PubMed ID: 33655889
[TBL] [Abstract][Full Text] [Related]
14. Identification of KIF4A and its effect on the progression of lung adenocarcinoma based on the bioinformatics analysis.
Song Y; Tang W; Li H
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33398330
[TBL] [Abstract][Full Text] [Related]
15. The potential bioactive ingredients and hub genes of five TCM prescriptions against lung adenocarcinoma were explored based on bioinformatics.
Liu T; Wei J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):2039-2055. PubMed ID: 36914901
[TBL] [Abstract][Full Text] [Related]
16. Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.
Yu L; Liang X; Wang J; Ding G; Tang J; Xue J; He X; Ge J; Jin X; Yang Z; Li X; Yao H; Yin H; Liu W; Yin S; Sun B; Sheng J
Genet Res (Camb); 2023; 2023():6782732. PubMed ID: 36688087
[TBL] [Abstract][Full Text] [Related]
17. Identifying the Antitumor Effects of Curcumin on Lung Adenocarcinoma Using Comprehensive Bioinformatics Analysis.
Yang FR; Li SY; Hu XW; Li XR; Li HJ
Drug Des Devel Ther; 2022; 16():2365-2382. PubMed ID: 35910781
[TBL] [Abstract][Full Text] [Related]
18. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M
Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
20. Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis.
Wang Y; Zhou Z; Chen L; Li Y; Zhou Z; Chu X
Mol Cell Biochem; 2021 Feb; 476(2):931-939. PubMed ID: 33130972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
